Some clinical characteristics of cord blood transplantation (CBT) might be explained by specificities in the reconstitution of immune subsets differing by their maturation stage or their implication in GVHD, tolerance or immune responses against tumor or infectious agents. Here, we compare the immune reconstitution of several of these subsets after CBT and BMT. B-cell count recovery was faster after CBT. There was no difference in the recovery of CD4 þ and CD8 þ cell counts. There was no difference either in the frequency of several subsets: CD45RO þ memory, and CD45RA þ naïve cells within the CD4 þ T-cell compartment, CD27 
INTRODUCTION
Almost all lethal complications of hematopoietic SCT, including leukemia relapse, and opportunistic infections, result from the post-transplant immune deficiency that lasts for months after transplantation. Therefore, the therapeutic challenge in improving the outcome for transplanted children outcome relies on the enhancement of immune reconstitution and the GVL effect, without increasing the harmful GVHD.
Although lower rates of engraftment and GVHD and higher rates of life-threatening infections have been reported in patients who received cord blood transplantation (CBT), similar EFS and leukemia relapse rates have been observed after CBT and BMT. [1] [2] [3] [4] [5] These observations indicate that cord blood-derived immune cells have unique immune properties that allow for allogeneic tolerance while preserving the GVL effect.
Previous studies have compared the reconstitution of the major immune cell populations after CBT and BMT: CD4 þ and CD8 þ T cells, natural killer (NK) and B cells. They showed that T-cell recovery is delayed, in particular CD8 þ T-lymphopoiesis after CBT, 2,6-9 although T-cell diversity has been shown to be similar in cord blood (CB) and BM recipients beyond 1 year after transplant. 7, 10 Conversely, innate immunity recovery has been shown to be similar between CB and BM recipients, with normal cell counts of functional NK cells in the blood as soon as 1-month post-CBT. 2, 11, 12 Finally, B-cell number recovery appears to be faster after CBT. 6, 9, 13 Besides these differences in the reconstitution of the major lymphocyte populations, additional changes in the reconstitution of other immune cell subsets might occur and explain some of the clinical differences observed in patients who receive BMT or CBT.
We, therefore, performed a longitudinal study of 40 pediatric patients receiving CBT or BMT to treat malignant or non-malignant diseases. We first determined the CD4 þ , CD8 þ , NK-and B-cell counts and then investigated the reconstitution of cell subsets differing by their maturation stages or implicated in immune tolerance and regulation, in patients receiving CBT or BMT. Within the CD4 þ T-cell compartment, we explored three maturation stages: naïve CD45RA þ , recent thymic emigrant CD45RA þ CD31 þ and CD45RO þ memory cells. [14] [15] [16] [17] [18] [19] [20] Within the B cells, we explored the CD27 þ memory subset. [21] [22] [23] NK-cell maturation stages were explored by studying the CD56 bright , NKG2A þ and KIR þ cells. [24] [25] [26] Finally, we compared the recovery of cells involved in immune regulation, GVHD and GVL, by examining the proportion of invariant NKT (iNKT) cells within the CD3 population, [27] [28] [29] and CD25 þ FOXP3 þ T regulatory (Treg) cells within the CD4 þ compartment. 30, 31 Together, these results reveal that NK-cell reconstitution is more sustained post-CBT than post-BMT, whereas thymopoiesis is delayed in CBT patients as compared with BM recipients.
PATIENTS AND METHODS Patients
Informed consents were obtained in accordance with the Declaration of Helsinki after CHU Sainte Justine IRB approval. Blood samples were collected 1, 2, 3, 6, 9 and 12 months after transplantation. Patient and transplant characteristics are summarized in Table 1 . Data were collected for 16 BMT and 39 CBT children, for a total of 55 enrolled between 2005 and 2010. In all, 4 BMT and 11 CBT patients were excluded from the analysis because of graft failure or relapse before engraftment. In case of leukemia relapse after engraftment, data were censored at the time 1 of relapse. Grafts were not in vitro T-cell depleted. HLA-A and -B typing was performed by serology for CB and by low-resolution DNA typing for BM donors. High-resolution DNA typing was used for HLA-DRB1 for both CB and BM donors until January 2009 and for HLA-A, -B, -C, DQB1 for BM donors since 2009. GVHD prophylaxis for related BMT patients included a short course of metothrexate and CsA until 6 months after transplant. Unrelated patients received CsA until 10 months post-transplant and anti-thymocyte globulins (Thymoglobulin, Genzyme, Cambridge, MA, USA), 2 mg/kg on days À 2, À 1, þ 1, þ 2. In CBT patients (all unrelated), GVHD prophylaxis also included i.v. methylprednisolone followed by oral prednisolone tapered until 50 days post-transplant. Unrelated BMT patients received also a short course of metothrexate. Supportive care was identical for all patients except for the G-CSF, administered only after CBT from day þ 5 until neutrophil recovery (days þ 20 to 30). 32 Determination of T-, B-and NK-cell counts and of lymphocytes subsets proportions
Absolute lymphocyte counts were determined using the hematological analyzer SYSMEX XE-alpha (SYSMEX Corporation, Kobe, Japan), whereas T-, Band NK-cell absolute numbers per microliter (mL) of blood were calculated from flow cytometry data and lymphocyte counts. Whole blood cells were stained, using anti-CD4 APC (clone SK3) or CD8 APC (clone SK1), CD45RA PE (clone ALB11) or CD45RO PE (clone UCHL1) and CD31 FITC (clone WM59) antibodies for naïve and memory CD4 þ ; using anti-CD4 FITC (clone SK4), CD25 PE (clone 2A3) and FOXP3 APC (clone PCH101) for Tregs identification; using anti-TCR Vbeta 11 FITC (clone C21), TCR Valpha 24 PE (clone C15) and CD3 APC (clone SK7) for iNK-T identification; using anti-CD19 FITC (clone HIB19) and CD27 PE (clone 1A4CD27) for memory B cells; using anti-CD158a FITC (clone HP-3E4), CD158b FITC (clone CH-L), CD159 PE (clone Z199), CD3 PE-Cy7 (clone UCHT1) and CD56 APC (clone B159 
Statistical analysis and definition of normal ranges
All statistical analyses were performed using the Prism 4 software (GraphPad Software, San Diego, CA, USA). Intergroup comparisons were assessed using the Mann-Whitney U-test, with significance defined by Po0.05 using a two-tailed test. Whenever available, normal ranges for children of similar ages were indicated. Normal values of lymphocyte subsets have been defined by the range (10-90%) of values obtained in a cohort of 450 healthy children (median age, 11 years, similar to our cohort of patients), except for NK-cell subsets. As NKG2A and KIR expression is not routinely explored in children, for NK-cell subsets, normal values have been defined by the range of values obtained in a cohort of 13 healthy adults.
RESULTS

Total T-, B-and NK-cell counts CD4
þ and CD8 þ T cells were barely detectable during the first 3 months post transplantation and remained lower than the normal range during the first 9 months post transplant (Figures 1a and b) . No difference was observed between CBT and BMT recipients for CD4 þ and CD8 þ T-lymphocyte count recovery.
B-cell counts were higher in CBT recipients as soon as 3 months post-transplant. Median B-cell counts remained below normal levels for 6 months post-BMT, whereas it was within the normal range as soon as 3 months after CBT, and even higher than normal at 9 and 12 months after transplant ( Figure 1c ). Of note, these levels of B-cell counts observed at 9 and 12 months are considered normal in children under 4 years of age (600-2000 cells per mL).
NK-cell blood counts in CB recipients were significantly higher than in BM recipients at 3, 9 and 12 months posttransplantation. Blood NK-cell counts reached normal values as soon as 1-month post-transplantation, regardless of the stem cell source (Figure 1d ). Immune reconstitution after transplant in children E Charrier et al Naïve and memory CD4 þ T cells During the first 6 months post transplant, CD4 þ T lymphocytes were mainly of memory phenotype (CD45RO þ ) in both transplant settings (Figure 2a ). In addition, there was no difference in the recovery of CD45RO þ and CD45RA þ subsets between CBT and BMT. CD45RA þ CD4 þ T cells, which include central and recent thymic emigrant CD4 þ T cells, gradually appeared in the blood, reaching normal levels 1-year post-transplant (Figure 2b ).
Children transplanted with CB had a lower proportion of recent thymic emigrant CD31 þ CD45RA þ CD4 þ T cells at 6 months posttransplantation (Figure 2c ). The proportion of these thymic naïve T cells was similar after CBT and BMT at any other time points, and did not reach the normal range before 1-year post transplant in either transplant settings.
Memory B cells The proportions of CD27
þ memory among B cells were similar between CB and BM recipients at any time point. Although the proportion of CD27 þ memory among CD19 þ B cells increased gradually during the follow-up, it never reached the range observed in healthy subjects of similar age even after 1-year post-transplantation (Figure 3 ). Of note, the percentage of CD27 Immune reconstitution after transplant in children E Charrier et al to the one observed in 1-year-old healthy subjects (median 7, 10th and 90th percentiles 4-12).
NK-cell maturation stages
The proportion of CD56 bright , NKG2A þ or KIR þ expressing cells was similar between CB and BM recipients during the first year post-transplant. The fraction of NK cells expressing high levels of CD56 surface marker (CD56 bright ) was initially elevated but gradually decreased during the first year post transplant (Figure 4a ). The proportion of NKG2A inhibitory receptor expressing NK cells decreased over time (Figure 4b) , whereas the proportion of NK cells expressing killer Ig-like receptors (KIRs, that is, CD158a and CD158b) increased during the follow-up (Figure 4c ).
We found a difference in the reconstitution of two NK-cell subsets differing in their maturation stage and responsiveness to tumor challenge: the double-negative NKG2A À KIR À subset and the double-positive NKG2A þ KIR þ subset (Figures 4d and e) . 25, 26 The proportion of NK cells belonging to the hyper-responsive double-positive subset was higher after CBT at most of the time points, whereas the proportion of double-negative hyporesponsive subset was more prominent after BMT.
þ Treg recovery following transplantation was similar for CBT and BMT patients (Figure 5a ). The proportion of CD4 þ T cells that were CD25 þ FOXP3
þ reached the normal range as soon as the CD4 þ T lymphocytes were detectable, regardless of the stem cell source (Figure 5a ). The proportion of Tregs among the CD4 þ T cells then increased above the normal range values at 2 and 3 months post transplant in both groups, and returned to normal levels after 6 months post transplant.
No differences were detected between CBT and BMT patients for the reconstitution of the iNKT cell compartment, defined by the expression of the invariant Vb11Va24 ab-T-cell receptor. iNKT frequency was highly variable from patient to patient, although its median was within normal range at 1-month post transplant in both groups, coinciding with the detection of CD3 lymphocytes (Figure 5b ).
DISCUSSION
In this study, we have compared the immune reconstitution of lymphoid populations that might impact the outcome of CBT and BMT. The reconstitution of total NK-and B-cell numbers was faster after CBT. Thymopoiesis was evaluated by the enumeration 
þ (e) NK cells are represented ± s.e.m. for each time point of the follow-up for patients transplanted with BM (white bars) and CB (black bars). Normal range of values is indicated as dotted lines (10-90% range for healthy adults). Mann-Whitney t-test was used to compare BM and CB samples and P-values are indicated where significant. NS, nonsignificant.
Immune
Their recovery appeared to be slower after CBT, as CD45RA þ CD31 þ cells appear earlier in the blood after BMT. The KIR þ NKG2A þ NK-cell subset recovered more rapidly, whereas the proportion of KIR À NKG2A
À cells was lower after CBT. We did not find any difference in the recovery of CD4 þ , CD8 þ counts, and neither in the frequency of the other subsets we studied:
þ memory and CD45RA þ naïve cells within the CD4 þ compartment, iNKT cells among T cells, CD27 þ among B cells, and CD56 bright , NKG2A þ , and KIR þ subsets within the NK cells. When studying CD4 þ T-cell expansion and maturation, we observed a higher proportion of CD4 þ CD45RA þ CD31 þ thymic naïve CD4 T cells at 6 months after transplant in the BMT group, demonstrating a slower recovery of thymopoiesis after CBT. We can exclude a difference in thymic function because of a difference in age, as patients' age does not differ between groups. As more patients transplanted for malignant diseases were included in the CBT group, previous exposure to chemotherapy might explain the impairment in thymic function in CBT patients. However, the proportion of CD4 þ CD45RA þ CD31 þ thymic naïve CD4 T cells at 6 months was comparable in the patients having received CBT for malignant and non-malignant diseases (three patients). As all patients received anti-thymocyte globulin in the CBT group vs only three in the BMT group, one may hypothesize that the impairment in thymic function might be attributed to the use of anti-thymocyte globulin in the conditioning regimen. However, the use of anti-thymocyte globulin did not impact the proportion of thymic naïve CD4 þ cells at 6 months after transplant in the BMT group. Finally, a low proportion of new thymic emigrants until 6 months after CBT has also been reported in adult patients, using T-cell receptors excision circle as a marker of thymopoiesis. [33] [34] [35] Taken together, these data suggest that thymopoisesis recovery is indeed slower after CBT, through a mechanism that remains to be elucidated.
We showed that reconstitution of CD8 þ cells counts was similar after CBT and BMT, but we did not explore CD8 þ thymopoiesis in this study. However, we recently studied CD45RA and CCR7 expression of CD8 þ cells in 30 patients transplanted in our unit during the same period, 15 of them being included in this study. We showed that the recovery of the naïve CD8 T cells CD45RA þ
CCR7
þ occurred at 6 months after CBT. 36 This suggests that there is no major difference between CD4 þ and CD8 þ T cells thymopoiesis after CBT. Both CD4 þ and CD8 þ thymopoiesis take place between 6 months and 1 year after CBT. Such a late thymopoiesis recovery explains the higher frequency of opportunistic infections after CBT.
B-cell expansion, but not maturation, appears to be more rapid after CBT. Indeed, B-cell number recovery was more rapid after CBT, but the proportion of CD27 þ memory B cells was identical at any time point, and still remains below the normal range for children at 1-year post transplant. Rapid recovery of B-cell numbers after CBT, already described by others, 2, 6, 8, 9 can be attributed to a higher proportion of B-cell precursors in cord blood. 37 B-cell maturation after CBT remains suboptimal at 1-year post-transplant, as already described with other graft sources. 22 As B-cell maturation needs an interaction with CD4 þ T cells in germinal centers, the slow B-cell maturation after CBT may be explained at least in part by the length of CD4 þ maturation. Another explanation could be that B-cell maturation after CBT recapitulates B-cell maturation of the infant. Indeed, B-cell counts as well as CD27 þ proportion at 1-year post-CBT are in the range of the values observed in 1-year-old healthy subjects.
NK-cell numbers were in the normal range as soon as 1 month after transplant in both groups, and NK-cell numbers were higher in CBT patients since 3 months after transplant. This is in accordance with previous reports. 2, 6, 38, 39 In the current model of NK-cell maturation, NKG2A þ cells predate KIR þ cells and CD56 bright cells predate CD56 dim cells. [24] [25] [26] Using this model, we did not find any difference in NK-cell maturation. 40 Our data furthermore support this model, as CD56 bright and NKG2A þ NK cells are preponderant in the first months and decrease over the first year after transplant, whereas KIR þ cells percentage increases during the same period. 41, 42 Interestingly, we found a difference in the frequency of doublepositive NKG2A
þ KIR þ and double-negative NKG2A À KIR À NK cells. Double-positive NK cells are reported to have enhanced degranulation capacity in response to tumor challenge. 43 Their frequency is higher after CBT. Conversely, double-negative NK cells are hyporesponsive against tumor targets.
43,44 Their frequency is lower after CBT. These data, together with a more sustained NK-cell count recovery, suggest that after CBT NK cells may have an advantage over post-BMT NK cells in their activity against tumor targets.
We did not find any difference in the recovery of iNKT cells and CD4 þ CD25 þ FOXP3 þ Treg cells, two subsets that may have a role in GVHD as well as in the GVL effect. [27] [28] [29] [30] [31] [45] [46] [47] [48] As soon as T lymphocytes were detectable, at 1-month post-transplant, their content in iNKT cell was in the normal range. In the same way, the recovery of CD4 T lymphocytes is associated with a frequency of CD25 þ FOXP3 þ cells within the normal range as soon as 1-month post-transplant. This suggests that the recovery of the T-cell compartment included these two subsets whatever the hematopoietic SCT source. Thus, some immunological properties of CBT, such as the lower GVHD rate, cannot be explained by a difference in iNKT cells or in Treg reconstitution.
Taken together, our data points toward two important features of post-CBT immune reconstitution in children. First, thymopoiesis recovery is slower than after BMT; this may explain why the more 
